Human (Hu) lecithin-cholesterol acyltransferase (LCAT) is a key enzyme in the plasma metabolism of cholesterol. To assess the effects of increased plasma levels of LCAT, four lines of transgenic mice were created expressing a Hu LCAT gene driven by either its natural or the mouse albumin enhancer promoter. Plasma LCAT activity increased from 1. The physiologic substrates for LCAT are nascent and mature HDL. Human (Hu) HDL is very heterogeneous both in particle size (5) and protein composition (6). HDL can be separated into two subpopulations on the basis of protein composition, one containing both apo AI and apo All (LpAI/AHI) and one containing apo AI but no apo All (LpAI). Both are heterogeneous in size (7). The size heterogeneity of Hu HDL distinguishes it from the monodisperse population of HDL particles present in the plasma of mice (8).
HDL plays a pivotal role in the transport of plasma cholesterol and is postulated to participate in a physiologic process called reverse cholesterol transport ( 1) -a process by which peripheral cell-derived cholesterol is transported through plasma to the liver for catabolism. Factors affecting this process by way of changes in the structure, composition, or concentration of plasma HDL particles are likely to have a profound effect on the homeostasis of plasma cholesterol.
Lecithin-cholesterol acyltransferase (LCAT)' is a 416-amino acid glycoprotein produced mainly by the liver that circulates in the plasma compartment as a functional unit with the cholesteryl ester transfer protein (CETP) and apo AI and apo D primarily in the HDL density range (2, 3) . LCAT, through its role in the esterification of cholesterol, promotes the packaging of this polar lipid into the core of the HDL particles, maintaining a concentration gradient for the diffusion of free cholesterol from peripheral tissues to HDL. Therefore, changes in the concentration and/or activity of this enzyme are likely to affect the transport of cholesterol by HDL. apo Al is the major protein component of HDL and the most potent activator of LCAT (4) .
The physiologic substrates for LCAT are nascent and mature HDL. Human (Hu) HDL is very heterogeneous both in particle size (5) and protein composition (6) . HDL can be separated into two subpopulations on the basis of protein composition, one containing both apo AI and apo All (LpAI/AHI) and one containing apo AI but no apo All (LpAI). Both are heterogeneous in size (7) . The size heterogeneity of Hu HDL distinguishes it from the monodisperse population of HDL particles present in the plasma of mice (8) .
LCAT is associated with transformation and remodeling of HDL. Plasma from LCAT-deficient patients (10, 11 ) contains small, discoidal HDL particles that probably represent nascent HDL (12) . These particles undergo marked changes in composition and morphology when LCAT is added, suggesting an essential role of this enzyme in the biogenesis of circulating HDL.
In this report, we established multiple lines of transgenic mice expressing the Hu LCAT gene at variable levels. To assess the impact of expressing Hu LCAT and to examine its substrate specificity, HuLCAT (Fig. 1 B) . The natural promoter region on the LCAT gene was removed by SphI digestion followed by ApaI partial enzyme digestion. Cohesive (Fig. 1) , separated from vector sequences by agarose gel electrophoresis, extracted from gels using the Geneclean kit (Bio 101, La Jolla, CA), and dialyzed in injection buffer (10 mM Tris-HCl, 1 mM EDTA, pH 7.4).
Creation of transgenic mice. Methods utilized in the creation of transgenic mice have been previously described (15) . Fertilized embryos used for the microinjection were derived from matings of inbred FVB mice (Charles River Laboratories, Wilmington, MA). The Hu apo AI and Hu apo All transgenic mice used in these studies have previously been described (16, 17) . These transgenic lines were created and maintained in the C57BL/6 background. In all the studies involving combinations of Hu apo Al, Hu apo All, and LCAT transgenes, the genetic background of each of the transgenic and control mice was (FVB x C57BL/6) F1 hybrids.
Preparation and analysis ofDNA and RNA by Southern and Northern blot. Tail tip DNA from 3-wk-old mice was screened for integration of Hu LCAT gene sequences by PCR. Primers were directed to synthesize the exon 6 of the Hu LCAT gene. Amplification reaction using nontransgenic mouse DNA as a template yielded no amplification products. In some experiments, integration of the full-length genomic construct was detected by Southern blot hybridization. 10 jig genomic DNA was digested overnight with 5 U Pstl/jig DNA, electrophoresed in a 1% agarose gel, and transferred to a nylon membrane (Sigma Chemical Co., S. Louis, MO). DNA was cross-linked to the membranes (Stratagene, La Jolla, CA) and hybridized with a 32P-radiolabeled full-length Hu LCAT cDNA as a probe.
RNA was isolated from transgenic and control mouse tissues (ovaries, brain, muscle, small intestine, kidney, heart, liver, spleen, and lung). Tissue (20) . Cholesterol esterification in total plasma was determined by the method described by Stokke and Norum (21 (25) in the presence and absence of cholesterol esterase, respectively. The plasma cholesteryl ester level is calculated as the difference between total and free cholesterol. Phospholipid concentrations were determined by the method described by Barlett (26) . Triglyceride concentrations were assayed using a diagnostic kit (44119; Roche Biomedical Laboratories, Burlington, NC). Values were corrected for the glycerol content.
Size fractionation of HDL. Total plasma lipoproteins (6 1.21 g/ ml) were isolated by ultracentrifugation of 50 ul fasted mouse plasma. Plasma was spun in a 42.2 rotor for 24 h at 40,000 rpm at 10°C. Total lipoproteins were collected and sieved in a 4-30% nondenaturing gradient gel electrophoresis (GGE) until equilibrium. HDL fractions were visualized by Coomassie blue staining of proteins, and the particle size distribution was determined by computer-assisted scanning densitometry as described (27) . The Quantification ofHDL subspecies. HDL species with pre-/3-mobility are lost during ultracentrifugation from the 6 5 1.21 g/ml lipoprotein fraction (28) . Therefore, to determine the proportion of prefl-and amigrating HDL species in the different groups of transgenic mice, 15 [1. native plasma was electrophoresed in 0.75% (wt/vol) agarose gel as previously described (2) and transferred to two nitrocellulose membranes (to avoid loss of apo AI migrating through the first membrane). To identify the Hu apo Al containing HDL species, nitrocellulose membranes were incubated for 2 h at room temperature with 2% milk in 10 mM phosphate buffer at pH 7.4 , and then with a protein G-purified 125I1 labeled rabbit anti-Hu apo AI antibody in 1% milk ( 1.5 X 106 cpm/ml), 10 mM phosphate buffer for 90 min. Unbound antibody was washed four times with 1% milk in phosphate buffer, and nitrocellulose membranes were exposed overnight to Kodak XAR-2 film (Eastman Kodak Rochestar, NY) at -70°C. No cross-reactivity was observed between this antibody and the murine apo AI HDL species in the nitrocellulose membrane, and the areas were cut out and counted in a gamma-spectrophotometer.
Statistical analysis. The results are expressed as means±SE. The statistical significance of the differences between the groups was esti- 
Results
Production of Hu LCAT transgenic mice and RNA expression. Two DNA fragments containing either the natural promoter element (Fig. 1 A) or the murine albumin enhancer-promoter linked to the LCAT gene ( Fig. 1 B) were microinjected into fertilized eggs from FVB mice. Four transgenic founder animals containing construct A and three containing construct B were derived. HuLCAT14 and HuLCAT31 transgenic mice (derived from construct A) and Hu(a)LCAT22 and Hu(a)LCAT57 transgenic mice (derived from construct B) were propagated and chosen for further analysis.
The tissue-specific expression of LCAT was analyzed by Northern blot hybridization with species-specific probes. Total RNA isolated from several tissues of control (Fig. 2 A) and transgenic mice containing the natural promoter elements (Fig.  2 B) was hybridized to the LCAT probes. The murine LCAT mRNA was abundant in the liver, while only small amounts were detected in the brain. Transgenic mice expressed the Hu transgene exclusively in the liver. No signal was detected in the brain. Previous transgenic studies that used exactly the same murine enhancer-promoter used in these studies have shown that sequences linked to this promoter express exclusively in the liver of transgenic animals (29) .
LCAT activity. Plasma LCAT activities of transgenic mice containing either the natural or the albumin enhancer-promoter increased by 1.2-to 1.6-fold over the nontransgenic control (Table I ). The greatest LCAT activity was observed in the HuAI/LCAT and HuAI/AH/LCAT mice, whereas the lowest levels were obtained in HuAI, HuAI/AII, and HuAT, HuAI/ AII, and HuAH/LCAT transgenic mice. The simultaneous presence of Hu apo Al and Hu LCAT was associated with the highest LCAT activities, whereas Hu apo All and Hu LCAT (2, 30) , essentially all the LCAT activity (94.8+7.6%; n = 5) was associated with the HDL lipoprotein fraction in nontransgenic control and HuLCAT transgenic mice. The high homology in the primary amino acid sequence between species (95% ) ( 31 ) did not allow us to obtain a specific antibody that will recognize and distinguish between mice and Hu LCAT. Thus, HuLCAT mass, and the effect of Hu LCAT on murine LCAT in the HuLCAT transgenic mice, was not determined.
Plasma lipids and lipoprotein analysis. The increase in plasma LCAT activities observed in HuLCAT transgenic mice (Table I) is associated with a 20-60% increase in plasma cholesterol and cholesteryl ester levels compared with nontransgenic controls. The increase in the cholesteryl esters was found almost exclusively in the HDL fraction. The ratio of cholesteryl esters to total cholesterol in HDL was very similar between the control mice and the different HuLCAT transgenic lines (ranging between 0.77 and 0.88 in the different lines). These data indicate that changes in the level of cholesteryl esters observed in HuLCAT transgenic mice are accompanied by similar increments in HDL-free cholesterol levels. To determine whether the increase in HDL-cholesterol is accompanied by a parallel increase in apo Al concentration, and thus an increase in the HDL number, murine apo AI levels were determined in pooled plasma from nontransgenic controls and HuLCAT transgenic mice containing either the natural promoter (HuL-CAT14 and HuLCAT3 1 ) or the albumin enhance-promoter sequences (Hu(a)LCAT22 and Hu(a)LCAT57). The apo Al concentration was 1.95 mg/dl in nontransgenic controls, 2.10 mg/ml and 2.13 mg/ml in HuLCAT14 + Hu LCAT31 and Hu(a)LCAT22 + Hu(a)LCAT57, respectively, suggesting that increasing amounts of plasma Hu LCAT do not associate with significant increases in plasma apo Al concentration.
Effect ofHu apo AI and Hu apo AII in plasma and lipoprotein cholesterol levels in HuLCAT transgenic mice. Hu HDL is very heterogeneous and differs from murine HDL in both particle size distribution and protein composition. Thus, the in vivo substrate specificity and the impact of Hu apo Al and Hu apo All (the two major proteins of Hu HDL) on Hu LCAT were assessed in transgenic mice expressing HuAI/LCAT, HuAI/AII/ LCAT, and HuAHILCAT.
The cholesterol levels in plasma of HuAI/LCAT31 and HuAI/(a)LCAT22 mice increased by 1.8-and 3.3-fold, respectively, over those found in HuLCAT31 and Hu(a)LCAT22 (Table I) . These changes were associated with increases in both cholesteryl esters and plasma free cholesterol, whereas the ratio of cholesteryl ester to total cholesterol was unaffected. Non-HDL cholesterol also increased in HuAI/LCAT transgenic mice. HuAI/LCAT31 transgenic mice had a 1.5-fold increase in VLDL + LDL-cholesterol compared with the HuLCAT31 transgenic mice. HuAI/(a)LCAT22 transgenic mice, despite doubling the LCAT activity, did not substantially increase the HDL-cholesterol compared with HuAl/LCAT3 1, but had a 4.7-fold increase in VLDL + LDL-cholesterol compared with the Hu(a)LCAT22 transgenic line. To determine whether the increase in VLDL + LDL-cholesterol is the consequence of an increased transfer of newly synthesized cholesteryl ester to apo B-containing lipoproteins, plasma containing tracer amounts of 3H-free cholesterol from HuAl and HuAI/LCAT transgenic mice was incubated for 30 min at 37°C. The distribution of 3H-labeled cholesteryl ester within plasma lipoproteins was determined by agarose gel electrophoresis. Only 6.1±2.0% (n = 4) and 9.8+1.5% (n = 4) of the labeled cholesteryl esters was detected in the apo B-containing lipoproteins in HuAI and HuAI/LCAT transgenic mice, respectively, indicating that a small proportion of cholesterol esterified by LCAT (28, 32) . HDL isolated by FPLC copurifies with plasma proteins, and therefore its protein concentration cannot be determined. Hu apo AI levels were thus used to monitor changes in particle size. The HDLs from HuLCAT and HuAI/LCAT transgenic mice (Table II) show an increase in free and esterified cholesterol compared with controls. However, the identical ratio of free cholesterol to cholesteryl ester in both groups of animals and the similar apo Al concentration observed in HuAI and HuAI/LCAT transgenic mice suggest Hu LCAT overexpression led to an increase in the HDL size rather than in the number of particles.
HDL particle size distribution. HDL, isolated by ultracentrifugation (6 c 1.21 g/ml) from the plasma of nontransgenic FVB mice, consisted of a monodisperse population of particles with a peak diameter of 10.6 nm as determined by GGE. The HuLCAT transgenic mice had a similar size distribution of HDL particles (data not shown). As previously reported (16) , HDL isolated from HuAl transgenic mice consisted of a bimodal distribution of particles with peak sizes of 8.9 and 11 nm, corresponding to Hu HDL2a and HDL2b (Fig. 4 A) . A third but smaller population at 7.8 nm was also observed. Major changes were observed in particle sizes of HDL isolated from the plasma of HuAI/LCAT and HuAI/AII/LCAT transgenic mice. HDL isolated from HuAI/LCAT31 transgenic mice (low expressor) showed predominant peaks (Fig. 4 B) of large particles (12.6, 11.2, and 10.2 nm) located within the HDL2b interval. HDL particle distribution from HuAI/(a)LCAT22 transgenic mice (high expressor) (Fig. 4 B) consisted of multiple peaks ranging in size from 14.6 to 7.4 nm. Interestingly, the less prominent but distinct peaks of smaller particles (8.2 and 7.4 nm) in the HDL3a and HDL3c intervals only occurred in high LCAT expressors, suggesting a dose effect.
In agreement with the observations of Schultz et al. (17), the HDL isolated from HuAI/All transgenic mice (Fig. 4 C) consisted of two major overlapping populations of particles within the HDL3a-tO-HDL3b size intervals. A minor population of particles that appear as a shoulder on the predominant peak with a 10.5-nm diameter was also observed. Expression of Hu LCAT together with Hu apo Al and apo All results in a marked redistribution of the particle sizes (Fig. 4 D) . The majority of the HDL particles were distributed into a larger population of particles with the peak particle size in the HDL2b interval, which corresponds to a minor population observed in HuAI/AII animals. HDL from transgenic mice expressing Hu apo All (Fig.  4 E) shows a bimodal distribution, with a predominant peak (9.3 nm) in the HDL2a size interval and a smaller peak at 7.7 nm (HDL3c) . When Hu LCAT was overexpressed in the HuAII transgenic mice, there was a slight increase in particle size of the major peak (9.7 nm), but no change in size of the smaller HDL3c peak (7.7 nm). Thus, the expression of Hu LCAT did not significantly alter the size distribution of HDL isolated from HuAII transgenic mice, although the peak particle size of the major HDL subpopulation (HDL2a) was greater in the HuAII/ LCAT mice.
Quantification ofpre/3-migrating HDL levels. Native plasma from human, HuAl, and HuAI/AII transgenic and nontransgenic control mice was fractionated by agarose gel electrophoresis and immunoreacted with a 251I-labeled rabbit antibody to Hu apo AI (Fig. 5) . Murine apo Al showed no cross-reaction with an antibody against Hu apo AI. HDL isolated from HuAI and HuAI/AII transgenic mice contained 18.4+3.7% and 7.8+1.2%, respectively, of the total Hu apo Al radioactivity migrating in the position corresponding to the Hu prep-migrating HDL species (Table III) . The balance of the apo Al immunoreactivity was found in the a-migrating HDL. Expression of the Hu LCAT transgene alone did not affect the migration of either pre/3-or the a-migrating HDL species. In HuAI/LCAT and HuAI/AII/LCAT transgenic mice, the prep-migrating HDL fraction decreased to 6.0+1.6% and 5.7%, representing 67 and 27% reductions in the proportion of apo Al in the pref3-migrating HDL fraction, respectively (P < 0.05). The total apo Al radioactivity was not significantly different between HuAI/ LCAT and HuAI, HuAI/AII/LCAT, and HuAI/AII transgenic mice. Furthermore, the plasma apo Al concentration was not different between HuAI/LCAT and HuAI transgenic mice (3.14 and 3.04 mg/ml, respectively), indicating that the lower proportion of prep3-migrating HDL represents a decrease in the plasma concentration of pre/3-HDL particles because of a redistribution of apo AI within the HDL fractions.
Discussion
The creation of HuLCAT transgenic mice, as described in this study, provides a model to study the regulation of this gene and its effect on HDL composition and structure. In humans (13), mice (31 ) , and monkeys (33), LCAT gene expression has been primarily detected in the liver and, to a lesser extent, in the testis and the brain. The LCAT genomic construct used in this study expressed exclusively in the liver and suggests that the sequence-specific elements required for liver expression are present in the 561 bp of the 5' untranslated region.
Despite the increase in HDL-cholesterol levels observed in HuLCAT transgenic mice, the HDL remained a monodisperse population of particles without a significant change in size or apo AI concentration. This suggests that murine HDL is able to accommodate some increases in free and esterified cholesterol without dramatic size changes. The dramatic changes in HDL size observed in mice with both Hu apo AI and Hu LCAT suggests that failure to observe significant HDL size changes in the HuLCAT mice results from either structural constraints of murine HDL to accept a significantly higher amount of cholesteryl ester or a poor ability of Hu LCAT to associate with and/or be activated by murine HDL. The latter is probably consistent with the higher plasma LCAT levels observed in HuAI/LCAT and HuAI/AII/LCAT transgenic animals compared with the HuLCAT transgenic animals. Alternatively, the different levels of plasma LCAT activity observed in the various combinations of transgenes could reflect the differences in LCAT removal. This agrees with the proposed divergent metabolic pathways of LpAI and LpAI,AII HDL subclasses (34) .
The most potent physiologic activator of LCAT is apo AI (4) . Several (42, 43) , the preference of Hu LCAT for HDL containing Hu (rather than mouse) apo Al has not been shown previously.
The effect of apo All on HDL metabolism and LCAT activation remain unclear. Our results in vivo suggest that particles containing Hu apo All alone or chimeras containing murine apo Al and Hu apo All are a poorer substrate for the Hu LCAT than HDL containing Hu apo AT. HDL particles containing both Hu apo Al and apo All do increase their cholesterol content followed by a transformation to larger particles, whereas HDL containing Hu apo All, but lacking Hu apo Al, do not undergo a similar size transformation. This supports the importance of Hu apo Al in determining the degree of cholesteryl ester accumulation and subsequent enlargement of HDL by the activity of Hu LCAT. The lower levels of cholesteryl esters formed in HuAI/AII/LCAT compared with HuAI/LCAT mice are possibly the consequence of the proposed effect of apo All in displacing the Hu apo Al and LCAT from the surface of HDL particles (44) and indirectly modulating LCAT activity. Areas containing pre-fl-and a-migrating HDL were cut out and counted in a gamma-spectrophotometer. Values are mean±SE from the number of mice indicated in parentheses. 8.9 A.
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The increase in LCAT activity in HuAI/LCAT transgenic mice is associated with an increase in the cholesterol content of VLDL + LDL lipoproteins. This result was unexpected because of the absence of CETP activity in mouse plasma (8) . We ruled out the possibility that this increment was the consequence of a transfer of cholesterol from HDL to the apo Bcontaining particles in HuAI/LCAT transgenic mice. Furthermore, no LCAT activity was associated with the VLDL + LDL lipoprotein fraction. However, it is possible that a fraction of LCAT associates with the VLDL + LDL fraction in HuAI/ LCAT transgenic mice and synthesizes cholesteryl esters as proposed in Fish-eye disease (45) . Alternatively, the increase in VLDL + LDL cholesterol could be explained by an increase in liver synthesis of cholesterol and subsequent secretion as part of the VLDL.
Of the variety of functions attributed to HDL, perhaps the most clinically relevant are those associated with reverse cholesterol transport. Pre,3-migrating HDL are the initial acceptor of cell-derived cholesterol (pre-01) (46) , but also part of the later esterification and transfer of cell-derived cholesterol (pre-,l2
and pre-/33) to a-migrating HDL (2) . As shown in this study, the expression of Hu apo Al in mice resulted in two major populations of HDL particles with identical electrophoretic mobility, as pref3-and a-HDL migrating species present in Hu plasma. The decrease in the proportion of prefp-migrating HDL observed in HuAI/LCAT and HuAI/AII/LCAT transgenic mice confirms the suggested relationship between pre3-HDL levels and LCAT (47-49). Incubation of plasma at 37TC in the presence or absence of LCAT inhibitors strongly suggests the conversion of pre/3-migrating HDL into a-migrating HDL without a net loss of apo Al. Although our measurements probably reflect a steady state rather than a dynamic conversion determined by kinetics, it seems reasonable to assume the decrease in prep3-migrating HDL levels is the consequence of the transformation of pre#3-HDL apo Al to a-HDL by the action of LCAT.
The lack of CETP activity in mouse plasma may account not only for the accumulation of large HDL subpopulations but also for the decrease in the level of prep3-migrating HDL observed in HuAI/LCAT and HuAl/AII/LCAT transgenic mice. In this study, we have shown that increasing LCAT activity is associated with a transformation of prefi-HDL and an increase in HDL-cholesterol levels. Further studies, including kinetic and atherosclerosis assays, need to be performed on the various lines of transgenic mice described in the present report to establish a direct link between cell-derived cholesterol transport, LCAT, and its effect on the prevention of atherosclerosis.
